Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Ebiomedicine|June 16, 2024
Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohortsJulie Lecuelle, Caroline Truntzer, Debora Basile, et al.
Oncoimmunology|May 8, 2026
Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohortsJulie Lécuelle, Caroline Truntzer, Debora Basile, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 16, 2024
Oxaliplatin-induced peripheral neuropathy with hepatic arterial versus intravenous infusion in metastatic colorectal cancerMarine Valéry, Marie-Laure Tanguy, Maximiliano Gelli, et al.
Cancer Research|April 9, 2009
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patientsCédric Ménard, Jean-Yves Blay, Christophe Borg, et al.
International Journal of Molecular Sciences|October 29, 2025
Plasma Protein Biomarkers to Detect Early Gastric Preneoplasia and Cancer: A Prospective StudyQuentin Giai Gianetto, Valérie Michel, Thibaut Douché, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2011
Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapyAziz Zaanan, Jean-François Fléjou, Jean-François Emile, et al.
Journal of Cancer|May 22, 2014
ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant ChemotherapyAziz Zaanan, Cécile Dalban, Jean-François Emile, et al.
Therapeutic Advances in Medical Oncology|November 20, 2025
Characteristics of KRAS WT pancreatic adenocarcinomas: results of a large French multicentric cohortNoémie Trystram, Jérome Cros, Hélène Blons, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 28, 2020
Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trialJulien Taïeb, Thierry André, Farid El Hajbi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM)Isabelle Trouilloud, Anne-Claire Dupont-Gossard, David Malka, et al.
Pageof 5